target and capturing

Scil Proteins Announces New Management Team and Revised Focus

Halle, Germany - 8 May 2014 - Scil Proteins, the expert company in Affilin®-based protein engineering, today announced that Dr Henning Afflerbach has been appointed as chief executive officer (CEO) and Dr Ulrich Haupts is named managing director, in addition to his current role as chief scientific officer (CSO).

The new management team will focus on driving the commercialization of Scil Proteins’ proprietary Affilin® platform. Core focus areas will be the development of drug conjugates and multi-specific protein binding molecules, as well as ligands for non-therapeutic applications, such as innovative diagnostics. The company is fully owned by BioNet Ventures GmbH. Early 2014, BioNet Ventures sold Scil Proteins’ sister company and microbial manufacturing specialist Scil Proteins Production to Wacker Biotech GmbH. BioNet Ventures remains the only shareholder of Scil Proteins.

Dr Afflerbach commented: “I am excited about my new role as CEO of Scil Proteins and very much look forward to working closely with Dr Ulrich Haupts in continuing to support our biopharma and life sciences partners with the generation and optimization of unique Affilin®-based protein therapeutics, diagnostics and bioreagents.”

Dr Ulrich Haupts added: “It is a pleasure working with Scil Proteins’ outstanding team of highly motivated protein engineering specialists and leveraging our fully automated high-throughput screening, bioinformatics and assay development platforms to expand the applicability of our Affilin®-based biomolecules in areas where conventional approaches, including antibodies, have their limitations.”

Prior to taking on his new role as CEO, Dr Afflerbach was responsible for leading business development and strategic planning for both Scil Proteins and Scil Proteins Production as chief business officer. He joined the Company in 2009 following various roles within Peptor GmbH/Ltd (Rehovot, Israel/Erkrath, Germany), Develogen AG (Göttingen, Germany) and DIREVO Biotech AG (Cologne, Germany).

Dr Haupts joined Scil Proteins as CSO in 2011 after more than 15 years of experience in both large pharma and biotech companies, including Bayer Healthcare AG (Cologne, Germany), DIREVO Biotech AG and SmithKline Beecham (Harlow, UK).

Affilin®-based biomolecules are derived from human scaffold proteins and have high stability, affinity and specificity making them ideal for a range of applications, including those where antibodies have limitations, thus broadening the potential of biotherapeutics.